Australia markets closed

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
24.58+0.24 (+0.97%)
As of 11:39AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close24.34
Open24.40
Bid24.18 x 100
Ask24.55 x 100
Day's range23.90 - 24.58
52-week range4.00 - 31.01
Volume21,649
Avg. volume88,709
Market cap370.729M
Beta (5Y monthly)2.25
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

    REDWOOD CITY, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today is presenting preclinical data demonstrating the effect of briquilimab on hematopoietic stem cells (HSCs) at the European Hematolo

  • GlobeNewswire

    Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

    REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress pre

  • GlobeNewswire

    Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

    REDWOOD CITY, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Jefferies Global Healthcare Conference at 4:00pm EDT on Wednesday, June 5, 2024. A live webcast